The following is from the Gold in Sacks report dated 17 Feb 2021.
"Management quantifies the total addressable opportunity at US$2bn, and whilst PMEhas 40 Visage contracts globally (of which 22 are in the US), we estimate a theoreticaladdressable opportunity in the US exceeding >5k hospitals (albeit likely skewed towards>100 academic facilities in the near term)."
I would add that with the inclusion of AI, and PME's development of other products, the realistic estimate of the addressable market has probably increased since GS wrote the report.
Also, I noted the following in the interview released to the ASX: "So, whilst we don’t provide forecasts, we have told the market that we anticipate a step-up in transaction volumes in FY22"
And in the webcast, in respect to exam (transaction) revenue, Dr Hupert said the following: "We are telling the market that we expect this growth to be a step change or a step growth in FY22..."
These guys generally don't say much about future performance, rather, they just quietly deliver. So a mention of a step change in exam revenue for FY22 gets my attention.
Cheers
PME Price at posting:
$64.88 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)